Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.
Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.
A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).
A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.
Watch an expert in lung cancer discuss the treatment options for patients with early-stage EGFR-mutant NSCLC
Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.
A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).
A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.
Watch an expert in lung cancer discuss the treatment options for patients with early-stage EGFR-mutant NSCLC
Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.
Watch Prof. Barbara Burtness provide an update on the evolving role of ICIs in the management of RM-NPC.
Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.
Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.
Watch an expert in RCC discuss multidisciplinary team care for patients with early through advanced disease.
touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events
Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL
Watch Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment.
Watch an oncology nurse and a medical oncologist discuss the use of HER2-directed ADCs in breast cancer.
An oncologist and a pathologist discuss HER2 testing and treatments for HER2-altered NSCLC.
Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.
Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.
Prof. Powles considers the latest developments in the treatment of advanced urothelial carcinoma.
Hear expert insights on the role of immunotherapy in treating advanced/recurrent endometrial cancer.
Watch GI oncologists discuss navigating the biomarker landscape to implement personalized treatment in CRC.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.